Meeting
2014 ASCO Annual Meeting
RAINBOW: A global, phase III, randomized, double-blind study of ramucirumab plus paclitaxel versus placebo plus paclitaxel patients with previously treated gastric or gastroesophageal junction (GEJ) adenocarcinoma: Quality-of-life (QoL) results.
Authors
Salah-Eddin Al-Batran
Krankenhaus Nordwest, Frankfurt, Germany
Salah-Eddin Al-Batran , Eric Van Cutsem , Sang Cheul Oh , Gyorgy Bodoky , Yasuhiro Shimada , Shuichi Hironaka , Naotoshi Sugimoto , Oleg N. Lipatov , Tae-You Kim , David Cunningham , Philippe Rougier , Kei Muro , Astra M. Liepa , Shaila Ballal , Michael Emig , Atsushi Ohtsu , Hansjochen Wilke
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer
Clinical Trial Registration Number
NCT01170663
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 4058)
DOI
10.1200/jco.2014.32.15_suppl.4058
Abstract #
4058
Poster Bd #
145
Abstract Disclosures
Similar Posters
Poster
2021 Gastrointestinal Cancers Symposium
RAINBOW-Asia: A randomized, multicenter, double-blind, phase III study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in the treatment of advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma following disease progression on first-line chemotherapy with platinum and fluoropyrimidine.
First Author: Rui-hua Xu
Poster
2015 Gastrointestinal Cancers Symposium
RAINBOW: A global, phase 3, double-blind study of ramucirumab (RAM) plus paclitaxel (PTX) versus placebo (PL) plus PTX in the treatment of advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma following disease progression on first-line platinum- and fluoropyrimidine-containing combination therapy—An age-group analysis.
First Author: Kei Muro
Poster
2018 ASCO Annual Meeting
The BRIGHTER trial: A phase 3 randomized double-blind study of napabucasin (NAPA) plus paclitaxel (PTX) versus placebo (PBO) plus PTX in patients (pts) with pretreated advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma.
First Author: Manish A. Shah
Poster
2016 Gastrointestinal Cancers Symposium
Characterizing tumor responses from RAINBOW, a randomized phase III trial of ramucirumab (RAM) plus paclitaxel (PAC) vs placebo (PBO) plus PAC in patients (pts) with previously treated advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.
First Author: Gyorgy Bodoky